Nicotinamide activates latent HIV-1 ex vivo in ART suppressed individuals, revealing higher potency than the association of two methyltransferase inhibitors, chaetocin and BIX01294
AUTOR(ES)
Samer, Sadia; Arif, Muhammad Shoaib; Giron, Leila Bertoni; Zukurov, Jean Paulo Lopes; Hunter, James; Santillo, Bruna Teresa; Namiyama, Gislene; Galinskas, Juliana; Komninakis, Shirley Vasconcelos; Oshiro, Telma Miyuki; Sucupira, Maria Cecilia; Janini, Luiz Mario; Diaz, Ricardo Sobhie
FONTE
Braz J Infect Dis
DATA DE PUBLICAÇÃO
2020-04
RESUMO
ABSTRACT Background: Latent HIV-1 is a major hurdle in obtaining HIV-1 sustained virological remission (SVR). Here we explored histone deacetylation inhibition property of nicotinamide (NAM; n = 17) for the first time in comparison to a combination of methyltransferase inhibitors (MTIs; Chaetocin and BIX01294; n = 25) to reactivate latent HIV ex vivo in CD8-depleted PBMCs from antiretroviral treated aviremic individuals. Results: NAM reactivated HIV-1 from 13/17 (76.4%) samples compared to 20/25 (80.0%) using MTIs with mean viral load (VLs) of 4.32 and 3.22 log10 RNA copies/mL, respectively (p = 0.004). Mean purging time after NAM and MTIs stimulation was 5.1 and 6.75 days, respectively (p = 0.73). Viral purging in autologous cultures exhibited blunted HIV recovery with fluctuating VLs followed by a complete viral extinction when expanded in allogenic system. Electron microscopy from five supernatants revealed anomalous viral particles, with lack of complete viral genomes when characterized by ultradeep sequencing through metagenomics approach (n = 4). Conclusion: NAM alone was more potent HIV-1 activator than combination of MTIs, with potential of clinical use.
Documentos Relacionados
- Association Between HIV-1 RNA Level and CD4 Cell Count Among Untreated HIV-Infected Individuals
- Inhibitors of HIV-1 replication that inhibit HIV integrase.
- Promoter choice affects the potency of HIV-1 specific RNA interference
- Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo
- HIV-1 protease inhibitors and the MDR1 multidrug transporter.